搜索历史清除全部记录
最多显示8条历史搜索记录噢~
全部
  • 全部
  • 产品管理
  • 新闻资讯
  • 介绍内容
  • 企业网点
  • 常见问题
  • 企业视频
  • 企业图册

+
  • epiboxrs.jpg

InVivoMAb抗尼帕病毒(NiV)糖蛋白G抗体(SAA2190)

InVivoMAb抗尼帕病毒(NiV)糖蛋白G抗体(SAA2190),InVivoMAb Anti-Nipah virus/NiV Glycoprotein G Antibody (SAA2190),非常适合开展中和反应和ELISA等实验类型。更多视频请关注视频号【艾维缔】。哔哩哔哩【IVDSHOW】。抖音【军哥聊表观】。


关键词

InVivoMAb抗尼帕病毒(NiV)糖蛋白G抗体(SAA2190)


所属分类


目录号

VVV07902

  • 产品描述
  • 产品组分
  • 文件资源
  • 营销中心
  • 注意事项
  • FAQ
  • 文献追踪
  • Species reactivity

    Nipah virus (NiV)

    Host species

    Human

    Isotype

    IgG1

    Clonality

    Monoclonal

    Target

    Glycoprotein, G

    Concentration

    1 mg/ml

    Endotoxin level

    Please contact with the lab for this information.

    Purity

    >95% as determined by SDS-PAGE.

    Purification

    Protein A/G purified from cell culture supernatant.

    Accession

    Q4VCP5

    Applications

    ELISA, Neutralization

    Form

    Liquid

    Storage buffer

    0.01M PBS, pH 7.4.

    Stability and Storage

    Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

    Clone ID

    SAA2190

  • 产品组分

    内容

    型号

    规格

    储存温度

    InVivoMAb抗尼帕病毒(NiV)糖蛋白G抗体(SAA2190)

    VVV07902-01 100ug -20°C

    InVivoMAb抗尼帕病毒(NiV)糖蛋白G抗体(SAA2190)

    VVV07902-02 1mg -20°C

    操作手册

    1 1

    常温室温

  • 文件资源

    文件下载

    文件内容

    资源说明

    VVV07902-InVivoMAb抗尼帕病毒(NiV)糖蛋白G抗体(SAA2190)

    操作手册

    VVV07902-InVivoMAb抗尼帕病毒(NiV)糖蛋白G抗体(SAA2190)相关单页

    宣传单页

     

  • 营销中心1

  • 注意事项

    保存建议 厂家推荐蓝冰运输。当您收到产品后,按照说明书建议保存于-20°C。

     

  • FAQ

     

  • Design and Preliminary Immunogenicity Evaluation of Nipah Virus Glycoprotein G Epitope-Based Peptide Vaccine in Mice., PMID:40333318

    A monoclonal antibody targeting the Nipah virus fusion glycoprotein apex imparts protection from disease., PMID:39240113

    An in vivo BSL-2 model for henipavirus infection based on bioluminescence imaging of recombinant Cedar virus replication in mice., PMID:38770087

    Computer-assisted identification of potential quinolone derivatives targeting Nipah virus glycoprotein attachment with human cell surface receptor ephrin-B2: Multistep virtual screening., PMID:37442011

    Assessment of the immunogenicity and protection of a Nipah virus soluble G vaccine candidate in mice and pigs., PMID:36274696

    Computational Identification of Potential Multitarget Inhibitors of Nipah Virus by Molecular Docking and Molecular Dynamics., PMID:35744699

    Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates., PMID:34696372

    Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy., PMID:32933033

    Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches., PMID:32377531

    Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study., PMID:32027842

    A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection., PMID:31686101

    Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities., PMID:30866781

    Generation of therapeutic antisera for emerging viral infections., PMID:30323953

    Two highly similar LAEDDTNAQKT and LTDKIGTEI epitopes in G glycoprotein may be useful for effective epitope based vaccine design against pathogenic Henipavirus., PMID:26970211

    Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection., PMID:25392218

    Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction., PMID:23698741

    Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo., PMID:23192877

    Nipah virus infection and glycoprotein targeting in endothelial cells., PMID:21054904

    A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection., PMID:19888339

    Ephrin-B2 expression critically influences Nipah virus infection independent of its cytoplasmic tail., PMID:19108727

    Evidence of a potential receptor-binding site on the Nipah virus G protein (NiV-G): identification of globular head residues with a role in fusion promotion and their localization on an NiV-G structural model., PMID:16840334

    Henipaviruses: recent observations on regulation of transcription and the nature of the cell receptor., PMID:15119767

    Potent Cross-neutralizing Antibodies Reveal Vulnerabilities of Henipavirus Fusion Glycoprotein., PMID:40298900

    Structural biology of Nipah virus G and F glycoproteins: Insights into therapeutic and vaccine development., PMID:40261700

    Serological and molecular analysis of henipavirus infections in synanthropic fruit bat and rodent populations in the Centre and North regions of Cameroon (2018-2020)., PMID:39994638

    Malaysia outbreak survivors retain detectable Nipah antibodies and memory B cells after 25 years., PMID:39755279

    Functional assessment of the glycoproteins of a novel Hendra virus variant reveals contrasting fusogenic capacities of the receptor-binding and fusion glycoproteins., PMID:39704501

    Establishing an immune correlate of protection for Nipah virus in nonhuman primates., PMID:39702562

    Immunogenicity and Neutralization of Recombinant Vaccine Candidates Expressing F and G Glycoproteins against Nipah Virus., PMID:39340029

    Ferritin nanoparticle-based Nipah virus glycoprotein vaccines elicit potent protective immune responses in mice and hamsters., PMID:39293542

    Isolation and characterization of IgG3 glycan-targeting antibodies with exceptional cross-reactivity for diverse viral families., PMID:39292703

    An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection., PMID:39217188

    Streamlined detection of Nipah virus antibodies using a split NanoLuc biosensor., PMID:39194145

    Fully human single-domain antibody targeting a highly conserved cryptic epitope on the Nipah virus G protein., PMID:39134522

    Measures to prevent and treat Nipah virus disease: research priorities for 2024-29., PMID:38964362

    A highly effective ferritin-based divalent nanoparticle vaccine shields Syrian hamsters against lethal Nipah virus., PMID:38911870

    Nano-Assembled Polyphosphazene Delivery System Enables Effective Intranasal Immunization with Nipah Virus Subunit Vaccine., PMID:38812435

    A Luciferase Immunosorbent Assay Based on Attachment Glycoprotein for the Rapid and Easy Detection of Nipah Virus IgG Antibodies., PMID:38792812

    A potent Henipavirus cross-neutralizing antibody reveals a dynamic fusion-triggering pattern of the G-tetramer., PMID:38773072

    Evaluation of the immunogenicity of an mRNA vectored Nipah virus vaccine candidate in pigs., PMID:38726013

    Structure and design of Langya virus glycoprotein antigens., PMID:38593070

    Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates., PMID:38569014

    Prefusion stabilization of the Hendra and Langya virus F proteins., PMID:38214525

    Inactivated Recombinant Rabies Virus Displaying the Nipah Virus Envelope Glycoproteins Induces Systemic Immune Responses in Mice., PMID:38140162

    Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8., PMID:38100536

    Both chimpanzee adenovirus-vectored and DNA vaccines induced long-term immunity against Nipah virus infection., PMID:37925490

    In silico prediction of interaction between Nipah virus attachment glycoprotein and host cell receptors Ephrin-B2 and Ephrin-B3 in domestic and peridomestic mammals., PMID:37924857

    Predicting the changes in neutralizing antibody interaction with G protein derived from Bangladesh isolates of Nipah virus: molecular dynamics based approach., PMID:37643003

    Recombinant Soluble Henipavirus Glycoprotein Preparation., PMID:37610572

    Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV., PMID:37577376

    Immunogenicity of poxvirus-based vaccines against Nipah virus., PMID:37452062

    A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses., PMID:37243163

    Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein., PMID:36932063

    Development and laboratory evaluation of a competitive ELISA for serodiagnosis of Nipah and Hendra virus infection using recombinant Nipah glycoproteins and a monoclonal antibody., PMID:36816187

    Establishment of a neutralization assay for Nipah virus using a high-titer pseudovirus system., PMID:36680637

    Distinct VSV-based Nipah virus vaccines expressing either glycoprotein G or fusion protein F provide homologous and heterologous protection in a nonhuman primate model., PMID:36508878

    Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease., PMID:36445779

    An Immunoinformatics Prediction of Novel Multi-Epitope Vaccines Candidate Against Surface Antigens of Nipah Virus., PMID:35761851

    Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential., PMID:35759511

    Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant., PMID:35617431

    A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease., PMID:35286211

    Architecture and antigenicity of the Nipah virus attachment glycoprotein., PMID:35239409

    Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine., PMID:34956199

    Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins., PMID:33927387

    Prediction of the binding interface between monoclonal antibody m102.4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking., PMID:33106487

    Vaccines to Emerging Viruses: Nipah and Hendra., PMID:32991264

    Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development., PMID:32595632

在线留言

如果您对我们的产品感兴趣,请留下您的信息,我们将尽快与您联系,谢谢!

图片名称

艾维缔官网

图片名称
图片名称

艾德官网

图片名称
图片名称

B站IVDSHOW

图片名称
图片名称

抖音军哥聊表观

图片名称
图片名称

视频号艾维缔

图片名称
图片名称

小红书艾维缔

图片名称
图片名称

快手表观盒子

图片名称
图片名称

表观遗传学

图片名称

联系我们

Tel:+86-0313-5935521|18911529660

ADD:张家口市怀来县东花园镇哈工大研究院T8幢709

邮箱:1951545998@qq.com

留言咨询

如果您对我们的产品和服务感兴趣,请留下您的信息。

立即咨询 →

IVDSHOW

订阅我们,以便及时了解产品更新和特惠活动

%{tishi_zhanwei}%
售后反馈 →

免责申明:本网站销售的所有产品均不得用于人类或动物之临床诊断或治疗,仅可用于工业或者科研等非医疗目的。(获得国家相关部门批准的产品除外) 

版权所有:艾维缔科技怀来有限公司 

营业执照